يعرض 1 - 9 نتائج من 9 نتيجة بحث عن '"Angiotensin Receptor Antagonists / therapeutic use"', وقت الاستعلام: 1.59s تنقيح النتائج
  1. 1

    المصدر: Baptiste, P J, Wong, A Y S, Schultze, A, Cunnington, M, Mann, J F E, Clase, C, Leyrat, C, Tomlinson, L A & Wing, K 2022, ' Effects of ACE inhibitors and angiotensin receptor blockers : Protocol for a UK cohort study using routinely collected electronic health records with validation against the ONTARGET trial ', BMJ Open, vol. 12, no. 3, e051907 . https://doi.org/10.1136/bmjopen-2021-051907

    وصف الملف: application/pdf

  2. 2
  3. 3

    المساهمون: Cardiology

    المصدر: BMJ Open, Vol 11, Iss 3 (2021)
    BMJ Open
    BMJ open, 11(3). BMJ Publishing Group

    وصف الملف: application/pdf

  4. 4

    المصدر: Welsh, T, Gladman, J & Gordon, A L 2014, ' The Treatment of Hypertension in Care Home Residents : A Systematic Review of Observational Studies ', Journal of the American Medical Directors Association, vol. 15, no. 1, pp. 8-16 . https://doi.org/10.1016/j.jamda.2013.06.012

    وصف الملف: application/pdf; PDF

  5. 5

    المصدر: European Journal of Clinical Investigation, Vol. 45, No 3 (2015) pp. 274-87
    European journal of clinical investigation
    European Journal of Clinical Investigation

  6. 6

    المساهمون: Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA), De Bruyne, B, Fearon, Wf, Pijls, Nh, Barbato, Emanuele, Tonino, P, Piroth, Z, Jagic, N, Mobius Winckler, S, Rioufol, G, Witt, N, Kala, P, Maccarthy, P, Engstr?m, T, Oldroyd, K, Mavromatis, K, Manoharan, G, Verlee, P, Frobert, O, Curzen, N, Johnson, Jb, Limacher, A, N?esch, E, J?ni, P, Fame, 2 Trial Investigators, Cardiovascular Biomechanics

    المصدر: New England Journal of Medicine
    New England Journal of Medicine, Massachusetts Medical Society, 2014, 371 (13), pp.1208-17. ⟨10.1056/NEJMoa1408758⟩
    De Bruyne, Bernard; Fearon, William F; Pijls, Nico H J; Barbato, Emanuele; Tonino, Pim; Piroth, Zsolt; Jagic, Nikola; Mobius-Winckler, Sven; Riouffol, Gilles; Witt, Nils; Kala, Petr; MacCarthy, Philip; Engström, Thomas; Oldroyd, Keith; Mavromatis, Kreton; Manoharan, Ganesh; Verlee, Peter; Frobert, Ole; Curzen, Nick; Johnson, Jane B; ... (2014). Fractional Flow Reserve–Guided PCI for Stable Coronary Artery Disease. New England journal of medicine NEJM, 371(13), pp. 1208-1217. Massachusetts Medical Society MMS 10.1056/NEJMoa1408758 <http://dx.doi.org/10.1056/NEJMoa1408758>
    FAME 2 Trial Investigators 2014, ' Fractional flow reserve-guided PCI for stable coronary artery disease ', New England Journal of Medicine, vol. 371, no. 13, pp. 1208-1217 . https://doi.org/10.1056/NEJMoa1408758
    The New England Journal of Medicine, 371(13), 1208-1217. Massachussetts Medical Society

    وصف الملف: application/pdf

  7. 7

    المساهمون: Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Fédérale Toulouse Midi-Pyrénées, Service Pharmacologie Clinique [CHU Toulouse], Pôle Santé publique et médecine publique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Caisse Nationale d'Assurance Maladie des Travailleurs salariés (CNAMTS), Ministère de l'économie et des finances, Institut des Maladies Métaboliques et Casdiovasculaires (UPS/Inserm U1297 - I2MC), NantesU M, Dépôt

    المصدر: European Journal of Clinical Pharmacology
    European Journal of Clinical Pharmacology, 2012, 68 (11), pp.1533-1540. ⟨10.1007/s00228-012-1283-9⟩

    مصطلحات موضوعية: Male, Diclofenac, MESH: Aged Angiotensin Receptor Antagonists / therapeutic use* Angiotensin-Converting Enzyme Inhibitors / therapeutic use* Anti-Inflammatory Agents, Non-Steroidal / adverse effects* Antihypertensive Agents / therapeutic use* Cohort Studies Databases, Factual Diclofenac / adverse effects Drug Interactions Drug Monitoring Drug Therapy, Combination Female Follow-Up Studies Humans Hypertension / drug therapy* Male Middle Aged Models, Biological National Health Programs Piroxicam / adverse effects Proportional Hazards Models Retrospective Studies, Databases, Factual, National Health Programs, medicine.drug_class, [SDV]Life Sciences [q-bio], Angiotensin-Converting Enzyme Inhibitors, Pharmacology, digestive system, Models, Biological, Cohort Studies, Angiotensin Receptor Antagonists, Piroxicam, Pharmacotherapy, Medicine, Humans, Pharmacology (medical), Drug Interactions, skin and connective tissue diseases, Antihypertensive drug, Antihypertensive Agents, Aged, Proportional Hazards Models, Retrospective Studies, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Hypertension treatment, business.industry, Anti-Inflammatory Agents, Non-Steroidal, Retrospective cohort study, General Medicine, Pharmacoepidemiology, Middle Aged, digestive system diseases, [SDV] Life Sciences [q-bio], Blood pressure, Non steroidal anti inflammatory, Hypertension, Drug Therapy, Combination, Female, Drug Monitoring, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Cohort study, Follow-Up Studies

  8. 8
  9. 9